247marketnews.com announces LIXTE Biotechnology's LB-100, a novel therapy exploiting oncogenic signaling to treat cancer effectively.
Quiver AI Summary
247marketnews.com reports on a new manuscript published in Trends in Cancer regarding an international conference focused on using oncogenic signaling as a cancer treatment strategy. Co-sponsored by LIXTE Biotechnology Holdings, Inc., the conference highlighted LIXTE's lead compound, LB-100, which inhibits the protein phosphatase 2A (PP2A) to induce toxic signaling in cancer cells, leading to their self-destruction. This novel approach challenges traditional cancer therapies that typically inhibit signaling pathways. The findings presented at the conference demonstrate LB-100's potential to synergize with immunotherapy, reinforcing LIXTE's position as a leader in innovative cancer research. LIXTE is advancing clinical trials for LB-100, particularly in Ovarian Clear Cell Carcinoma.
Potential Positives
- Co-sponsorship of the first international conference on oncogenic signaling positions LIXTE as a leader in innovative cancer treatment strategies.
- Presentation of compelling data regarding LIXTE's lead compound LB-100 demonstrates its potential effectiveness in activating oncogenic signaling to combat cancer.
- The novel mechanism of action for LB-100 suggests it could enhance the efficacy of existing cancer therapies, making it a valuable addition to treatment options.
- The recognition of PP2A inhibition as a new therapeutic frontier solidifies LIXTE's role in advancing cancer research and therapy development.
Potential Negatives
- Forward-looking statements indicate significant risks and uncertainties surrounding the company's future business growth and operational viability.
- The company must navigate complex regulatory environments and clinical trial processes that may impact the development of LB-100.
- As a clinical-stage company, LIXTE's success is heavily reliant on the outcomes of ongoing trials, which pose inherent risks of failure.
FAQ
What is the significance of the recent conference on oncogenic signaling?
The conference highlighted the novel strategy of activating oncogenic pathways for cancer treatment, showcasing LIXTE's LB-100 compound.
How does LB-100 work as a cancer treatment?
LB-100 inhibits PP2A, removing a cellular “off switch” and triggering uncontrolled signaling that pushes cancer cells to self-destruct.
What were the key findings presented at the conference?
Key findings included LB-100's ability to induce tumor cell death and enhance synergy with immunotherapy and other treatments.
Who co-organized the international conference on oncogenic signaling?
The conference was co-organized by Professor Rene Bernards and LIXTE Biotechnology Holdings, showcasing their leadership in cancer research.
What is LIXTE's focus in cancer research?
LIXTE is focused on developing innovative cancer therapies targeting the PP2A pathway, with LB-100 as their lead compound.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$LIXT Hedge Fund Activity
We have seen 6 institutional investors add shares of $LIXT stock to their portfolio, and 5 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FNY INVESTMENT ADVISERS, LLC removed 107,000 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $96,835
- TIAA TRUST, NATIONAL ASSOCIATION removed 101,834 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $123,219
- CITADEL ADVISORS LLC removed 24,522 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $22,192
- UBS GROUP AG removed 7,179 shares (-86.6%) from their portfolio in Q2 2025, for an estimated $6,496
- TOWER RESEARCH CAPITAL LLC (TRC) added 3,332 shares (+inf%) to their portfolio in Q2 2025, for an estimated $3,015
- GEODE CAPITAL MANAGEMENT, LLC removed 2,337 shares (-10.1%) from their portfolio in Q2 2025, for an estimated $2,114
- ATLAS LEGACY ADVISORS, LLC added 1,064 shares (+8.4%) to their portfolio in Q2 2025, for an estimated $962
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
DENVER, Aug. 27, 2025 (GLOBE NEWSWIRE) -- 247marketnews.com , a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, highlights the publication of a new manuscript in Trends in Cancer (July 2025, Vol. 11, No. 7, https://doi.org/10.1016/j.trecan.2025.04.009 ) describing the first international conference on activation of oncogenic signaling as a cancer treatment strategy.
The landmark meeting was co-sponsored by LIXTE Biotechnology Holdings, Inc. (NASDAQ: LIXT) and co-organized by Professor Rene Bernards, and board member of LIXTE. At the conference, compelling new data was presented showing that LIXTE’s lead compound LB-100 can mediate activation of oncogenic signaling, a process that proves toxic to cancer cells.
A Paradigm Shift: Oncogenic Signaling as Therapy
Traditional cancer therapies have long focused on inhibiting oncogenic pathways. This meeting explored the counterintuitive strategy of activating these same pathways to push cancer cells beyond survival limits.
LB-100, a first-in-class PP2A inhibitor, exemplifies this novel approach. By inhibiting PP2A, LB-100 removes a cellular “off switch,” triggering uncontrolled signaling activity in cancer cells. This “lethal activation” drives cells into self-destruction, while also generating abnormal proteins (neoantigens) that make tumors more visible to immune attack.
LB-100: Expanding Validation Across Platforms
The conference reinforced the growing recognition of PP2A inhibition as a new therapeutic frontier. Presentations demonstrated:
- Oncogenic signaling activation: LB-100 induces hyperactivation of growth pathways that becomes unsustainable for tumor cells.
- Cancer cell toxicity: This signaling overload leads directly to tumor cell death.
-
Combination potential: The mechanism creates synergy with immunotherapy and other treatment modalities.
These findings further support LB-100’s unique role as a platform therapy designed to enhance the effectiveness of multiple cancer treatments.
Positioning LIXTE as a Global Thought Leader
By co-sponsoring this first-of-its-kind meeting, LIXTE underscored its leadership in advancing innovative therapeutic strategies. The company’s role as strategic organizer highlights its commitment to shaping the next chapter in cancer research.
About LIXTE Biotechnology Holdings, Inc.
LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company’s lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing a proof-of-concept trial in Ovarian Clear Cell Carcinoma.
More information can be found at: www.lixte.com
24/7 MARKET NEWS, INC Disclaimer
Please go to
https://247marketnews.com/lixte-biotechnology/
for further LIXT information and 247marketnews.com LIXT disclosure information.
CONTACT:
24/7 Market News
[email protected]
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.
